Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

O'Hare T, Zabriskie MS, Eiring AM, Deininger MW.

Nat Rev Cancer. 2012 Jul 24;12(8):513-26. doi: 10.1038/nrc3317. Review. Erratum in: Nat Rev Cancer. 2012 Dec;12(12):886.

PMID:
22825216
2.

BCR-ABL kinase is dead; long live the CML stem cell.

Perl A, Carroll M.

J Clin Invest. 2011 Jan;121(1):22-5. doi: 10.1172/JCI43605. Epub 2010 Dec 13.

3.

Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.

Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G.

Leuk Lymphoma. 2012 Dec;53(12):2351-61. doi: 10.3109/10428194.2012.695779. Epub 2012 Jun 18. Review.

PMID:
22616642
4.

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.

Eide CA, O'Hare T.

Curr Hematol Malig Rep. 2015 Jun;10(2):158-66. doi: 10.1007/s11899-015-0248-3. Review.

6.

State-of-the-art in the treatment of chronic myeloid leukaemia.

Milojkovic D, Apperley J.

Curr Opin Oncol. 2008 Jan;20(1):112-21. Review.

PMID:
18043265
7.

Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.

Kuroda J, Shimura Y, Yamamoto-Sugitani M, Sasaki N, Taniwaki M.

Curr Cancer Drug Targets. 2013 Jan;13(1):69-79. Review.

PMID:
22414011
8.
9.

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL.

N Engl J Med. 2001 Apr 5;344(14):1031-7.

10.

BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.

Leonetti F, Stefanachi A, Nicolotti O, Catto M, Pisani L, Cellamare S, Carotti A.

Curr Med Chem. 2011;18(19):2943-59. Review.

PMID:
21651486
11.

Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.

Beel K, Janssens A, Verhoef G, Vandenberghe P.

Leuk Res. 2009 Dec;33(12):1703-5. doi: 10.1016/j.leukres.2009.04.021. Epub 2009 May 19.

PMID:
19457553
12.

Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors.

Li S, Li D.

J Cell Mol Med. 2007 Nov-Dec;11(6):1251-62. doi: 10.1111/j.1582-4934.2007.00108.x. Review.

13.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

14.

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.

Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.

15.

Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.

Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A, Fekete S, Barta A, Ujj G, Lueff S, Sipos A, Adám E, Bors A, Reményi P, Masszi T, Tordai A, Andrikovics H.

Acta Haematol. 2012;127(1):34-42. doi: 10.1159/000331472. Epub 2011 Oct 14.

PMID:
22005133
16.

Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.

Valent P, Deininger M.

Leuk Lymphoma. 2008 Apr;49(4):604-9. doi: 10.1080/10428190801923212. Review.

PMID:
18398718
17.

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.

Zámečníkova A.

Expert Rev Hematol. 2010 Feb;3(1):45-56. doi: 10.1586/ehm.09.66. Review.

PMID:
21082933
18.

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Maekawa T, Ashihara E, Kimura S.

Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. Review.

PMID:
17929114
19.

Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.

Boeckx N, Laer CV, Roover JD, Wilmsen B, Bruyninckx K, Pauwels S.

Acta Clin Belg. 2015 Aug;70(4):237-43. doi: 10.1179/2295333715Y.0000000009. Epub 2015 Jul 13.

PMID:
26166681
20.

Getting to the stem of chronic myeloid leukaemia.

Savona M, Talpaz M.

Nat Rev Cancer. 2008 May;8(5):341-50. doi: 10.1038/nrc2368. Review.

PMID:
18385684
Items per page

Supplemental Content

Write to the Help Desk